Briganix 180 mg (Brigatinib) is a cutting-edge oral medication designed to treat ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in ALK-positive lung cancer. This medication is particularly effective for patients whose cancer has progressed…
Briganix 90 mg (Brigatinib) is an advanced oral medication specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in some forms of lung cancer. Briganix 90 mg is especially effective…
Crizocent 250mg (Crizotinib) is a highly effective targeted therapy specifically designed to treat advanced non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase) or ROS1-positive. This innovative medication works by blocking the activity of proteins (ALK and ROS1) that promote cancer cell growth, making it an essential treatment for patients with these specific genetic mutations. Crizocent is trusted…
